Corbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update August 9, 2022
Corbus Presents Latest Preclinical Data for CRB-601 at the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference May 11, 2022
Corbus Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update May 10, 2022
Corbus Presents First Preclinical Data for CRB-601 at the American Association for Cancer Research (AACR) Annual Meeting April 8, 2022
Corbus Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference March 11, 2022
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Updates March 8, 2022
Corbus Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Updates November 12, 2021
Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates August 12, 2021
Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis June 24, 2021
Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases June 1, 2021
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress May 25, 2021
Corbus Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Updates May 13, 2021
Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE) April 20, 2021
Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis March 30, 2021
Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2020 Results on March 15, 2021 March 8, 2021
Corbus Pharmaceuticals Announces Presentations at the New York Academy of Sciences Webinar on Targeting the Endocannabinoid System to Treat Human Diseases January 20, 2021
Corbus Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference November 12, 2020
Corbus Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Updates November 10, 2020
Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis November 9, 2020
